 The goal of this clinical research study is to use 68GA-DOTATOC instead of the standard-of-care 111-In-pentetreotide as a tracer chemical during PETCT scans for diagnosing neuroendocrine tumors. A tracer is injected into your bloodstream to help the study doctor see possible tumors. 